Breaking News Instant updates and real-time market news.

SGMO

Sangamo

$11.25

-0.02 (-0.18%)

, BMRN

BioMarin

$82.68

-2.49 (-2.92%)

08:41
07/12/19
07/12
08:41
07/12/19
08:41

Sangamo should be bought at current share levels, says Jefferies

Jefferies analyst Maury Raycroft attributes the recent weakness in shares of Sangamo Therapeutics (SGMO) to negative sentiment related to BioMarin's (BMRN) valrox's durability. The market may be assuming all hemophilia A gene therapies are the same, Raycroft tells investors in a research note. However, he believes Sangamo's SB-525 could be "best-in-class" and keeps a Buy rating on the shares with a $19 price target. The analyst recommends buying the stock at current levels for the company's hemophilia A opportunity and "robust" pipeline.

SGMO

Sangamo

$11.25

-0.02 (-0.18%)

BMRN

BioMarin

$82.68

-2.49 (-2.92%)

  • 09

    Sep

SGMO Sangamo
$11.25

-0.02 (-0.18%)

02/08/19
JEFF
02/08/19
NO CHANGE
Target $23
JEFF
Buy
Jefferies sees opportunity in Sangamo after selloff, drops target to $23
Jefferies analyst Maury Raycroft says his Buy thesis on Sangamo Therapeutics is unchanged following yesterday's update. The analyst lowered his price target for the shares to $23 from $26 and maintains a Buy rating. Sangamo demonstrated successful in vivo editing, Raycroft tells investors in a research note. The analyst has confidence in the company's update, noting Sangamo was able to detect an albumin-IDS mRNA transcript in a liver biopsy aspirate that extracted around 100,000-300,000 cells for analysis. Further, concern about patient six and the transaminitis is likely an overreaction as liver enzyme elevation is consistent across gene therapy programs, adds the analyst. Raycroft sees opportunity in Sangamo shares following yesterday's selloff.
02/08/19
GSCO
02/08/19
NO CHANGE
Target $21
GSCO
Buy
Goldman says Orchard track record stands out amid disappointments in gene space
Goldman Sachs analyst Graig Suvannavejh noted that February 7 was "a day of disappointment" in the gene therapy and gene editing space, as Solid Biosciences (SLDB) and Sangamo (SGMO) both reported clinical efficacy data that missed investor expectations and "perhaps also raised concerns about the long-term promise of gene-based approaches." Within this context, he pointed out that he believes Orchard Therapeutics (ORTX) has "the most robust clinical experience in gene therapy, with over 150 patients treated across multiple product candidates and indications." The analyst, who expects new clinical data for Orchard candidates OTL-101 and OTL-102 to be presented later this month to re-affirm his confidence, reiterated his Buy rating and $21 price target on Orchard shares.
04/02/19
WELS
04/02/19
NO CHANGE
Target $34
WELS
Outperform
Sangamo price target raised to $34 from $24 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Sangamo Therapeutics to $34 from $24 following this morning's clinical update on the company's gene therapy, gene editing and cell therapy pipeline. The stock in morning trading is up 35%, or $3.35, to $12.88. The update was better than expected, particularly for hemophilia gene therapy and beta thalassemia ex vivo gene editing, Birchenough tells investors in a research note. The analyst is "encouraged" by Sangamo's progress against the higher technical hurdle of in vivo genome editing. He believes direct evidence of genome editing, "strong" fetal hemoglobin response and early signs of transfusion independence bode well for ultimate success and should translate into improved likelihood of success in the larger opportunity of sickle cell disease. The analyst reiterates an Outperform rating on Sangamo Therapeutics.
07/08/19
PIPR
07/08/19
NO CHANGE
PIPR
Overweight
BioMarin's Valrox maintains competitive advantage, says Piper Jaffray
After BioMarin (BMRN) announced that the company will submit regulatory filings for Valrox to both the FDA and EMA in Q4, and after the company and competitive partners Sangamo (SGMO) and Pfizer (PFE) both presented updates at this weekend's International Society on Thrombosis and Hemostasis meeting, Piper Jaffray analyst Christopher Raymond said that he still believes the company's roughly 2-year head start puts Valrox at a competitive advantage. Following the confirmation on timing for accelerated filing, Raymond said he would continue to be a buyer of BioMarin shares and he keeps an Overweight rating on the stock.
BMRN BioMarin
$82.68

-2.49 (-2.92%)

06/18/19
JPMS
06/18/19
NO CHANGE
Target $133
JPMS
Overweight
BioMarin remains 'high conviction long-term idea' at JPMorgan
After hosting a call with the company's CEO Jean-Jacques Bienaime and Head of R&D Hank Fuchs, JPMorgan analyst Cory Kasimov says BioMarin remains a "high conviction long-term idea." The analyst highlights the company's orphan-focused, "diversified" base business, "growing" commercial portfolio, and "potentially disruptive" late-stage pipeline. The analyst notes that BioMarin management does not believe the company is are getting enough credit for its pipeline opportunities and that investor concerns around competitive risks are overblown. Kasimov reiterates an Overweight rating on BioMarin shares with a $133 price target.
07/08/19
GSCO
07/08/19
NO CHANGE
GSCO
Goldman Sachs looking to a mid-2020 BioMarin valrox approval
Goldman Sachs analyst Salveen Richter notes that BioMarin has announced plans to submit U.S. and EU marketing applications for its gene therapy valrox in adults with severe hemophilia A in Q4 post recent meetings with regulatory authorities. The analyst anticipates a drug launch in mid-2020-plus, noting that valrox addresses a $30B-$90B severe hemophilia A global opportunity. Richter looks to a Q4 R&D day and the gene therapy program for PKU entering the clinic and is positive into vosoritide Phase 3 results in achondroplasia.
07/10/19
WEDB
07/10/19
NO CHANGE
Target $128
WEDB
Outperform
BioMarin weakness 'a buying opportunity' ahead of Q4 catalysts, says Wedbush
Wedbush analyst Liana Moussatos notes that BioMarin has presented results from the valoctocogene roxaparvovec Phase 2 and Phase 3 studies. Following meetings with the FDA and EMA, BioMarin guided to submission of an NDA and MAA for Valrox/Severe Hemophilia A in Q4, she notes. The analyst believes that Valrox has a "clear development lead over" its competition, which may increase the commercial opportunity. Moussatos anticipates approval for Valrox/Hemophilia A as highly likely based on robust efficacy and safety data and projects annual sales could reach over $2B in 2023 after her U.S. estimated launch in year-end 2020. She sees current weakness in the stock as a buying opportunity in front of potentially major clinical and regulatory catalysts in Q4. Moussatos reiterates an Outperform rating and $128 price target on the shares.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$298.86

1.07 (0.36%)

, SPX

S&P 500

$0.00

(0.00%)

20:32
07/18/19
07/18
20:32
07/18/19
20:32
General News
Trump to nominate Gene Scalia as Secretary of Labor »

President Trump tweeted:…

SPY

SPDR S&P 500 ETF Trust

$298.86

1.07 (0.36%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$128.40

1.355 (1.07%)

, BLK

BlackRock

$474.98

4.06 (0.86%)

20:25
07/18/19
07/18
20:25
07/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

AXP

American Express

$128.40

1.355 (1.07%)

BLK

BlackRock

$474.98

4.06 (0.86%)

SLB

Schlumberger

$38.78

0.15 (0.39%)

SYF

Synchrony

$36.09

0.54 (1.52%)

STT

State Street

$56.27

1.67 (3.06%)

CFG

Citizens Financial

$34.62

0.27 (0.79%)

RF

Regions Financial

$14.76

0.06 (0.41%)

KSU

Kansas City Southern

$118.03

1.22 (1.04%)

ALV

Autoliv

$69.88

0.04 (0.06%)

GNTX

Gentex

$23.54

0.01 (0.04%)

MAN

ManpowerGroup

$90.30

0.82 (0.92%)

CLF

Cleveland-Cliffs

$10.88

-0.11 (-1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 06

    Aug

  • 06

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 27

    Aug

  • 27

    Oct

  • 13

    Nov

POST

Post Holdings

$108.09

0.64 (0.60%)

20:12
07/18/19
07/18
20:12
07/18/19
20:12
Upgrade
Post Holdings rating change at Piper Jaffray »

Post Holdings upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

VMW

VMware

$174.34

0.13 (0.07%)

19:01
07/18/19
07/18
19:01
07/18/19
19:01
Hot Stocks
VMware to acquire Bitfusion, terms not disclosed »

In a blog post, VMware…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

CRWD

Crowdstrike

$72.75

1.77 (2.49%)

, SKX

Skechers

$34.75

0.35 (1.02%)

18:50
07/18/19
07/18
18:50
07/18/19
18:50
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

CRWD

Crowdstrike

$72.75

1.77 (2.49%)

SKX

Skechers

$34.75

0.35 (1.02%)

EXPO

Exponent

$61.63

0.83 (1.37%)

MSFT

Microsoft

$136.29

0.06 (0.04%)

CHWY

Chewy

$32.79

1.14 (3.60%)

RRGB

Red Robin

$30.58

0.32 (1.06%)

GCI

Gannett

$7.90

-0.185 (-2.29%)

IFRX

InflaRx

$3.12

0.05 (1.63%)

BA

Boeing

$361.17

-8.28 (-2.24%)

MVIS

MicroVision

$0.86

0.0458 (5.62%)

OZK

Bank OZK

$28.61

0.5 (1.78%)

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

AA

Alcoa

$23.42

0.27 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 19

    Jul

  • 23

    Jul

  • 24

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 26

    Aug

  • 26

    Aug

  • 09

    Sep

  • 23

    Sep

  • 16

    Oct

MGM

MGM Resorts

$28.75

-0.095 (-0.33%)

, MGP

MGM Growth

$30.00

-0.06 (-0.20%)

18:50
07/18/19
07/18
18:50
07/18/19
18:50
Periodicals
MGM said to consider sale-leaseback of Bellagio, MGM Grand, Bloomberg says »

The report states the…

MGM

MGM Resorts

$28.75

-0.095 (-0.33%)

MGP

MGM Growth

$30.00

-0.06 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 06

    Aug

AAL

American Airlines

$33.75

0.5 (1.50%)

, UAL

United Continental

$95.27

0.44 (0.46%)

18:49
07/18/19
07/18
18:49
07/18/19
18:49
Periodicals
POTUS meets with U.S. airlines over Qatar subsidy accusations, Reuters says »

U.S. President Donald…

AAL

American Airlines

$33.75

0.5 (1.50%)

UAL

United Continental

$95.27

0.44 (0.46%)

JBLU

JetBlue

$19.23

0.14 (0.73%)

FDX

FedEx

$165.39

0.375 (0.23%)

AAWW

Atlas Air

$42.58

0.79 (1.89%)

BA

Boeing

$361.17

-8.28 (-2.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 01

    Aug

  • 17

    Sep

  • 13

    Nov

  • 14

    Nov

NUE

Nucor

$54.68

-0.03 (-0.05%)

18:44
07/18/19
07/18
18:44
07/18/19
18:44
Hot Stocks
Nucor CEO: We are very pleased with the results from the tariffs »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

NABZY

National Australia Bank

$0.00

(0.00%)

18:30
07/18/19
07/18
18:30
07/18/19
18:30
Hot Stocks
National Australia Bank names Ross McEwan as new CEO »

National Australia Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$29.48

0.3 (1.03%)

18:22
07/18/19
07/18
18:22
07/18/19
18:22
Hot Stocks
Bank of America CEO: Millennials are a huge customer base for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 06

    Sep

  • 16

    Oct

TAP

Molson Coors

$54.37

0.08 (0.15%)

18:06
07/18/19
07/18
18:06
07/18/19
18:06
Hot Stocks
Molson Coors raises quarterly dividend to 57c from 41c per share »

Molson Coors declared a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MSFT

Microsoft

$136.29

0.06 (0.04%)

18:04
07/18/19
07/18
18:04
07/18/19
18:04
Hot Stocks
Breaking Hot Stocks news story on Microsoft »

Microsoft up over 2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

BAS

Basic Energy

$1.81

-0.1 (-5.24%)

18:02
07/18/19
07/18
18:02
07/18/19
18:02
Hot Stocks
Basic Energy announces record setting lateral completion in Permian Basin »

Basic Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 13

    Nov

MSFT

Microsoft

$136.29

0.06 (0.04%)

18:02
07/18/19
07/18
18:02
07/18/19
18:02
Hot Stocks
Microsoft CFO continues to expect double digit revenue growth in FY20 »

Sees FY20 operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

QTRH

Quarterhill

$1.23

(0.00%)

18:02
07/18/19
07/18
18:02
07/18/19
18:02
Hot Stocks
WiLAN unit acquires patent portfolio from Vidiator »

Wi-LAN announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

18:00
07/18/19
07/18
18:00
07/18/19
18:00
Earnings
Microsoft sees total Q1 revenue at implied $31.7B-$32.4B, consensus $32.0B »

By segment: Sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

RRGB

Red Robin

$30.58

0.32 (1.06%)

18:00
07/18/19
07/18
18:00
07/18/19
18:00
Hot Stocks
Red Robin up 17% after confirming $40.00 per share offer from Vintage Capital »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$33.09

-0.17 (-0.51%)

17:54
07/18/19
07/18
17:54
07/18/19
17:54
Periodicals
AT&T mulls sale of Puerto Rican business to pay down debt, Bloomberg says »

AT&T, which is eyeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 30

    Jul

  • 08

    Aug

RRGB

Red Robin

$30.58

0.32 (1.06%)

17:53
07/18/19
07/18
17:53
07/18/19
17:53
Hot Stocks
Red Robin confirms $40.00 per share cash buyout proposal from Vintage Capital »

Red Robin confirmed it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

17:50
07/18/19
07/18
17:50
07/18/19
17:50
Hot Stocks
Microsoft CFO: Q4 another quarter of double-digit top and bottom line growth »

Says commercial bookings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

HBIO

Harvard Bioscience

$1.78

0.03 (1.71%)

17:46
07/18/19
07/18
17:46
07/18/19
17:46
Hot Stocks
Harvard Bioscience names Michael Rossi CFO »

Harvard Bioscience has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

17:43
07/18/19
07/18
17:43
07/18/19
17:43
Hot Stocks
Microsoft CEO seeing growing momentum across every layer of its stack »

Says LinkedIn saw record…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

17:38
07/18/19
07/18
17:38
07/18/19
17:38
Hot Stocks
Intuitive Surgical falls after Q2 report, despite earnings beat »

Shares of Intuitive are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 09

    Sep

GLD

SPDR Gold Shares

$136.44

1.85 (1.37%)

17:33
07/18/19
07/18
17:33
07/18/19
17:33
Hot Stocks
SPDR Gold Shares holdings rise to 814.62MT from 803.18MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAL

Western Alliance

$44.45

0.74 (1.69%)

17:29
07/18/19
07/18
17:29
07/18/19
17:29
Earnings
Western Alliance reports Q2 EPS 1.19, consensus $1.16 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 06

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.